Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Ronald J. Maggiore, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-0394

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Credentials

Specialties

  • Geriatric Medicine - American Board of Internal Medicine
  • Hematology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2004
MD | University of Illinois College of Medicine

Post-doctoral Training & Residency

07/01/2010 - 06/30/2013
Fellowship in Hematology/Oncology at University of Chicago Medical Center

07/01/2007 - 06/30/2010
Fellowship in Hematology at Yale New Haven Hospital

07/01/2005 - 06/30/2007
Residency in Internal Medicine at University of Wisconsin Hospital and Clinics

07/01/2004 - 06/30/2005
Internship in Internal Medicine at University of Wisconsin Hospital and Clinics

VIEW ALL expand_more

Awards

2016
OHSU Hematology/Oncology Fellows' Craig Okada Teacher of the Year Award
Sponsor: OHSU

2014
OHSU Department of Radiation Medicine, Radiation Medicine Residents' Interdisciplinary Excellence in Teaching Award
Sponsor: OHSU

Clinical Trials

A Phase 1b/2 study to evaluate safety and clinical activity of Avelumab in combination with NKTR-214 with or without TALAZOPARIB or ENZALUTAMIDE in patients with locally advanced or metastatic solid tumors

Lead Researcher: Ronald J Maggiore

This study will test the combination of drugs, avelumab + bempegaldesleukin (NKTR-214 ), in treating locally advanced skin cancer of the head and neck (metastatic squamous cell carcinoma). It will also look at avelumab + bempegaldesleukin (NKTR-214) + either talazoparib or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Inclusion Criteria: •Participants must be ≥ 18 years old. •Participants with squamous cell carcinoma of the head or neck or mCRPC.

View Study Details

Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol) (NRG-LU003)

Lead Researcher: Ronald J Maggiore

This National Cancer Institute (NCI)-NRG phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV, ALK positive, non-squamous, non-small cell lung cancer.ALK inhibitors like lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether a combination of biomarker/ALK inhibitors or chemotherapy may work better in treating patients with lung cancer.

View Study Details

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (NRG-HN005)

Lead Researcher: Ronald J Maggiore

This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its growth and may not have spread to other parts of the body (early-stage), and is not associated with smoking. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial is being done to see if a reduced dose of radiation therapy and nivolumab works as well as standard dose radiation therapy and cisplatin in treating patients with oropharyngeal cancer.

View Study Details

Nivolumab Versus Observation in Treating Patients With Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer (EA3161)

Lead Researcher: Ronald J Maggiore

This phase II/III trial studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy and radiation therapy followed by maintenance nivolumab therapy works better than chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal cancer.

View Study Details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated With Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Lead Researcher: Ronald J Maggiore

The purpose of the phase 3, clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

View Study Details

MK-7902-008: A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) (LEAP-008)

Lead Researcher: Ronald J Maggiore

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with an anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS); and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR).

View Study Details

CHAN17022: EA3132: Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery,CHAN17022: EA3132: Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Lead Researcher: Ronald J Maggiore

The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.

View Study Details

UHAN17040: Phase I/II Trial of the Addition of Palbociclib (PD 0332991) to Cetuximab in Patients with Incurable SCCHN,UHAN17040: Phase I/II Trial of the Addition of Palbociclib (PD 0332991) to Cetuximab in Patients with Incurable SCCHN

Lead Researcher: Ronald J Maggiore

If you participate in this study you will be taking palbociclib and cetuximab as treatment for your cancer. Palbociclib is taken by mouth once a day and cetuximab is given intravenously weekly.

View Study Details

Publications

Journal Articles

7/11/2019
Maggiore RJ, Strawderman MS, Victor AI, Archibald WJ. "Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience." Journal of geriatric oncology.. 2019 Jul 11; Epub 2019 Jul 11.

6/4/2019
Welaya K, Loh KP, Messing S, Szuba E, Magnuson A, Mohile SG, Maggiore RJ. "Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors." Journal of geriatric oncology.. 2019 Jun 4; Epub 2019 Jun 04.

1/30/2019
Muchnik E, Loh KP, Strawderman M, Magnuson A, Mohile SG, Estrah V, Maggiore RJ. "Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer." Journal of the American Geriatrics Society.. 2019 Jan 30; Epub 2019 Jan 30.

Books & Chapters

2019
Chapter Title: Oncologic and Hematologic Malignancies
Book Title: Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine
Author List: Maggiore RJ, Magnsuon A.
Edited By: Harper GM, Lyons WL, Potter JF
Published By: American Geriatrics Society 2019 in NY

2017
Chapter Title: Head and Neck Cancer in Older Adults
Book Title: Handbook of Geriatric Oncology
Author List: Maggiore, RJ; VanderWalde, NA; Crawley, M
Published By: Springer 2017

2009
Chapter Title: Lung Cancer
Book Title: Hazzard's Geriatric Medicine and Gerontology
Author List: Presley CJ, Maggiore RJ, and Gajra A
Published By: McGraw-Hill 2009

VIEW ALL PUBLICATIONS